FINWIRES · TerminalLIVE
FINWIRES

Anteris Technologies Secures US Medicare Reimbursement Eligibility for PARADIGM Trial

By

-- Anteris Technologies (ASX:AVR) said it has secured US Medicare reimbursement eligibility for its global pivotal PARADIGM Trial under a Centers for Medicare and Medicaid Services (CMS) national coverage policy, according to a Wednesday Australian bourse filing.

The PARADIGM Trial is evaluating the safety and effectiveness of the DurAVR transcatheter heart valve (THV) compared to transcatheter aortic valve replacements (TAVRs), with DurAVR THV being Anteris' product to treat aortic stenosis, a potentially life-threatening condition resulting from the narrowing of the aortic valve, the filing added.

The CMS framework operates under a Coverage with Evidence Development (CED) model, enabling reimbursement with clinical evidence generation.

The company said that securing this reimbursement eligibility is expected to facilitate US site activation and accelerate operational momentum across participating centers.

The company's shares rose 2% in recent Wednesday trade.

Related Articles

Asia

Brightstar Resources Reports Higher March Quarter Group Mining Production

Brightstar Resources (ASX:BTR) said its group mining production for the March quarter came in at 58,700 tonnes at 3.3 grams per tonne (g/t) grade of gold for 6,250 ounces from its Laverton underground mining operations in Western Australia, according to a Wednesday Australian bourse filing.The company's group mining production for the March 2025 quarter came in at 28,200 tonnes at 3.3 g/t grade of gold for 3,002 ounces from its Laverton underground mining operations in Western Australia, per the filing.During the quarter, the Fish underground mine was transitioned to care and maintenance, with mining operations ceasing and the mine positioned to be ready for the recommencement of ore production in early 2027.The mining development and closure proposal for Lady Shenton open pit mine in Menzies was approved, the filing said.Brightstar Resources' shares fell nearly 1% in recent trading on Wednesday.

$ASX:BTR
Asia

Racura Oncology, University of Wollongong Win New South Wales Government Funding for Cancer Study

Racura Oncology (ASX:RAC) and the University of Wollongong secured funding under the New South Wales government's TechVouchers program to study the efficacy of (E,E)-bisantrene for certain types of breast and ovarian cancers, according to a Wednesday filing with the Australian bourse.A collaboration between Racura and the University aims to produce preclinical evidence for the development of RC220 as a new targeted therapy, per the filing.Results from the collaboration are expected to come out over the next 12 months.Racura Oncology shares gained 2% in recent Wednesday trade.

$ASX:RAC
Asia

JAC Motors Widens Q1 Loss, Revenue Up 17%

Anhui Jianghuai Automobile (SHA:600418), or JAC Motors, posted first-quarter attributable net loss of 606.0 million yuan, compared with 223.0 million yuan the previous year.Loss per share widened to 0.27 yuan from 0.10 yuan, according to a Wednesday filing with the Shanghai bourse.The automobile company's operating revenue went up 17% year over year to 11.5 billion yuan from 9.80 billion yuan.

$SHA:600418